Developments and perspectives in allergology

Abstract

SummaryAllergology is a key part of dermatological care. This paper reviews current pathophysiological, diagnostic and therapeutic developments in immediate‐type allergies.Type‐2 inflammation is involved in several allergological diseases such as allergic rhinitis and asthma. Allergen immunotherapy as an important therapeutic procedure is regulated in Germany by an official legal directive (Therapieallergene‐Verordnung). Therapeutically, several biologics are already available that target interleukin (IL)‐4, ‐5, ‐13, ‐33, or TSLP (thymic stromal lymphopoietin). Collateral efficacy may result in simultaneous treatment of allergological comorbidities.In mast cell mediated diseases (urticaria, anaphylaxis), there is increasing understanding of mast cell activation pathways. Several mast cell receptors such as MRGPRX2 (mas‐related G protein coupled receptor X2) and Siglec‐8 (sialinic acid binding Ig like lectin‐8) as well as intracellular signaling pathways have recently been identified. Clinical trials are underway with drugs acting on mast cell receptors and intracellular signaling, i.e., Bruton's tyrosine kinase inhibitors.Further perspectives on biomarkers, novel therapeutics and unmet needs for future research activities are presented.